

November 13, 2024

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers, Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on November 13, 2024

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (13/11/2024):

1. Financial Results

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Period ended 30/09/2024 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records and for uploading in your website. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, will be published in English and Marathi newspapers within the time stipulated **Annexure-1.**

2. The Board of Directors on the recommendations of Nomination Remuneration Committee have approved the appointment of Mr. Vivek Balasubramanian as the Chief Financial Officer of the Company (Membership No. 261385) designated as the Key Managerial Personnel with effect from start of business hours on November 13, 2024 pursuant to the provisions of section 203 of the Companies Act, 2013 are given as **Annexure-2.**

3. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform the exchange that Mr. Dilip Suryakant Jha, Chief Financial Officer has decided to step down as Chief Financial Officer of the Company vide his letter dated November 08, 2024 and will be relieved from the services of the Company with effect from close of business hours on November, 12, 2024. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure-3**.

The Board Meeting commenced at 22.45 PM (IST) and concluded at 23.45 PM (IST)
Please take on record.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



FISCHER MEDICAL VENTURES LIMITED (formerly known as Fischer Chemic Limited)
CIN: L86900MH1993PLC288371

Regd Off: 104, First Floor Raghuleela Mega Mall Behind Poisar Depot Kandivali West, Mumbai, Maharashtra, India, 400067
Corp off: Level 5, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India
Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.09.2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs														
SL NO	PARTICULARS	STANDALONE						CONSOLIDATED						
		Quarter Ended			Half Year Ended			Quarter Ended			Half Year Ended			Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	Revenue From Operations	0.00	0.00	18.81	0.00	18.81	1152.83	3965.53	1012.07	0.00	4977.60	0.00	2098.13	
II	Other Income	81.96	112.23	1.33	194.19	1.33	75.05	22.35	74.17	0.00	96.52	0.00	50.12	
III	Total Income (I + II)	81.96	112.23	20.14	194.19	20.14	1227.88	3987.88	1086.24	0.00	5074.12	0.00	2148.25	
IV	Expenses													
	Cost of Materials Consumed	0.00	0.00	0.00		0.00	1072.36	0.00	0.00	0.00	0.00	0.00	1573.80	
	Purchase of Stock-In-Trade	6.50	0.00	0.00	6.50	0.00	0.00	4086.33	1751.84	0.00	5838.16	0.00	7.87	
	Changes In Inventories of Finished Goods, Work-In-Progress And Stock-In-Trade	(6.50)	0.00	0.00	(6.50)	0.00	0.00	(473.77)	(890.39)	0.00	(1364.17)	0.00	63.74	
	Employee Benefits Expense	4.18	2.53	0.91	6.71	1.53	5.50	50.60	39.31	0.00	89.91	0.00	38.09	
	Finance Costs	0.00	0.00	0.00	0.00	1.58	1.58	4.86	12.50	0.00	17.36	0.00	6.76	
	Depreciation and Amortisation Expenses	0.05	0.05	0.00	0.10	0.00	0.08	28.81	27.72	0.00	56.54	0.00	18.21	
	Other Expenses	31.44	8.70	3.58	40.14	12.57	94.49	252.98	128.94	0.00	381.92	0.00	228.66	
	Total Expenses	35.67	11.28	4.49	46.95	15.68	1174.01	3949.81	1069.92	0.00	5019.73	0.00	1937.13	
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	46.29	100.95	15.65	147.23	4.46	53.87	38.07	16.32	0.00	54.39	0.00	211.12	
VI	Exceptional Items							(17.05)	(8.71)		(25.77)			
VII	Profit / (Loss) Before Tax (V - VI)	46.29	100.95	15.65	147.23	4.46	53.87	21.02	7.61	0.00	28.62	0.00	211.12	
VIII	Tax Expense													
	Current Tax	5.00	17.00	1.24	12.00	1.24	3.00	5.00	17.00	0.00	(12.00)	0.00	3.00	
	Deferred Tax (Asset) / Liability	(0.01)	(0.01)	0.00	0.03	0.00	(10.59)	3.31	(2.32)	0.00	1.00	0.00	(24.33)	
	Reversal of Excess Provision / Provision For Taxation Relating To Earlier Years	-	-	-	-	-	-							
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	51.28	83.94	14.41	135.20	3.22	40.28	29.33	(11.71)	0.00	17.62	0.00	183.79	
X	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	
XI	Tax Expense of Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-	
XIII	Profit / (Loss) For The Period (IX + XII)	51.28	83.94	14.41	135.20	3.22	40.28	29.33	(11.71)	0.00	17.62	0.00	183.79	
XIV	Other Comprehensive Income													
	Items That Will Not Be Reclassified To Profit / (Loss)													
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	
	(ii) Income Tax Relating on Above	-	-	-	-	-	-	-	-	-	-	-	-	
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	
	Other Comprehensive Income - Total	-	-	-	-	-	-	-	-	-	-	-	-	
XV	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XVI	Paid Up Equity Share Capital (Face Value Re.10/-)	5350.00	5350.00	17.20	5350.00	17.20	5350.00	5350.00	5350.00	0.00	5350.00	0.00	5350.00	
XVII	Other Equity						2530.79						2674.30	
XVIII	Earnings Per Share (EPS)													
	(a) Basic EPS From Continuing Operations (In Rs.)	0.10	0.16	1.05	0.25	0.24	0.36	0.05	(0.02)	0.00	0.03	0.00	1.65	
	(b) Basic EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-	
	(c) Diluted EPS From Continuing Operations (In Rs.)	0.09	0.15	1.05	0.25	0.24	0.36	0.05	(0.02)	-	-	-	1.08	
	(c) Diluted EPS From Discontinued Operations (In Rs.)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	

Notes:

- The acquisition of 'M/s.Time Medical International Ventures (India) Private Limited' has been done during the Quarter four of the Previous financial year ended on 31st March 2024. Since consolidation has been done in the previous year quarter ended, There is No comparatives of previous year's figures as on quarter and period ended 30th Sept 2023.
- M/s.Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited).during the period under review has made overseas investments in the following companies:-
 - Flynncare Health Innovations P Ltd dated 27th July 24 ,
 - FMV Healthcare PTE Limited dated 26th Aug 24,
 - FMV International Ventures PTE Limited dated 26th Aug 24 all the stated company will be considered as another material subsidiary following 'M/s.Time Medical International Ventures (India) Private Limited'
- M/s.Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited).during the period under review has made overseas investments in Fischer Hospitality Sdn. Bdn. Dated -19th Sept 24 acquiring 60% of the Share Capital of the Company
- The above statement has been prepared to the extent applicable, in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.
- The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13/11/2024
- The Statutory Auditor of the Company have carried out a Limited Review of the above Standalone and Consolidated Financial Results for the Quarter / Half Year ended 30.09.2024 and their report was placed before the Board.
- The above is an extract of the detailed format of Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results are available in the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and Company's website at

// BY ORDER OF THE BOARD //

For Fischer Medical Ventures Limited
(for Fischer Chemic Limited)

Mr.Ravindran Govindan
Chairman & Managing Director



Date: 13/11/2024

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)						
CIN : L86900MH1993PLC288371						
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2024						
(Amount in lakhs)						
Particulars	Quarter Ended			Half Year Ended		Year ended
	30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I) Revenue From Operations	-	-	18.81	-	18.81	1,152.83
II) Other Income	81.96	112.23	1.33	194.19	1.33	75.05
III) Total Income (I+II)	81.96	112.23	20.14	194.19	20.14	1,227.87
IV) Expenses :						
Cost of Material Consumed	-	-	-	-	-	1,072.36
Purchase of Traded Goods	6.50	-	-	6.50	-	-
Changes in inventories of finished goods, by-products and work in progress	(6.50)	-	-	(6.50)	-	-
Employee Benefit expenses	4.18	2.53	0.91	6.71	1.53	5.50
Depreciation and Amortization Expenses	0.05	0.05	-	0.10	-	0.08
Finance Cost	-	-	-	-	1.58	1.58
Other Expenses	31.44	8.70	3.58	40.14	12.57	94.49
Total Expenses (IV)	35.67	11.28	4.49	46.95	15.68	1,174.01
V) Profit (Loss) Before exceptional and tax (III-IV)	46.29	100.95	15.65	147.23	4.46	53.87
VII) Share of Loss from Associate						
- The Therapy Platform Pte Ltd	-	-	-	-	-	-
- Bluesim tech pte ltd F'S	-	-	-	-	-	-
Profit/(loss) before exceptional items and tax (VII + VIII)	46.29	100.95	15.65	147.23	4.46	53.87
VI) Exceptional Items	-	-	-	-	-	-
Profit before tax (V-VI)	46.29	100.95	15.65	147.23	4.46	53.87
VIII) Tax Expenses						
i) Current Tax	5.00	(17.00)	(1.24)	(12.00)	(1.24)	(3.00)
ii) Deferred Tax	(0.01)	(0.01)	-	(0.03)	-	(10.59)
IX) Profit (Loss) from Continuing Operations (VII-VIII)	51.28	83.94	14.41	135.20	3.22	40.28
XIII) Profit (Loss) for the period (XI+XII)	51.28	83.94	14.41	135.20	3.22	40.28
XIV) Other Comprehensive income;						
A (i) Items that will not be reclassified to profit or	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (XIII-XIV)	51.28	83.94	14.41	135.20	3.22	40.28
XV) Earnings per Equity Shares						
1) Basic	0.10	0.16	1.05	0.25	0.24	0.36
2) Diluted	0.09	0.15	1.05	0.25	0.24	0.36
Summary of significant accounting policies						
Notes to accounts						

As per our report of even date

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR



Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900MH1993PLC288371

Standalone Balance Sheet As At September 30th, 2024

Particulars	As At 30-09-2024	As At 31-03-2024
Assets		
(1) Non-Current Assets		
Property, Plant & Equipment	0.48	0.58
Goodwill		
Deferred Tax Asset (Net)		
Right of use Asset		
Financial Assets		
(i) Investments	4,461.63	4,128.26
(ii) Others		
Total Non-Current Assets	4,462.11	4,128.84
(2) Current assets		
(a) Inventories	6.50	-
(b) Financial assets		
(i) Trade receivables	1,129.79	1,270.10
(ii) Cash and cash equivalents	142.31	0.38
(iii) Other Current Financial Asset		
-Loans	2,352.45	3,777.74
-Other Current Financial Asset	0.50	0.58
(c) Current Tax Asset(Net)	12.45	
(d) Other Current Assets	9.70	5.51
Total Current Assets	3,653.70	5,054.31
Total Assets	8,115.81	9,183.16
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	5,350.00	5,350.00
(b) Other Equity		
Reserve & Surplus	2,665.99	2,530.79
Money received against share warrants	87.15	87.15
Total Equity	8,103.14	7,967.94
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability	0.05	0.20
(b) Financial Liabilities		
(i) Borrowings		-
Total Non-Current Liabilities	0.05	0.20
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Short Borrowings		-
Lease Liabilities		
(ii) Trade payables		
total outstanding dues of micro enterprises and small enterprises		0.31
total outstanding dues of creditors other than micro enterprises and small enterprises		
	4.61	1,203.43
(iii) Other Financial liabilities	4.33	2.56
Provision		-
(b) Other Current Liabilities	3.68	8.90
Total Current Liabilities	12.62	1,215.20
Total Equity and Liabilities	8,115.81	9,183.16
		-
The accompanying notes are an integral part of the financial statements.		
As per our report of even date		

For FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR



Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900MH1993PLC288371

Cash Flow Statement as at September 30, 2024

(Amount in lakhs)

PARTICULARS	For the period ended 30-09-2024	For the year ended 31-03-2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit / (Loss) before tax and Extra Ordinary items	147.23	53.87
<u>Adjustment for:-</u>		
Finance Cost	-	1.58
Depreciation	0.10	0.08
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	147.34	55.52
<u>Adjustment for:-</u>		
(Increase)/decrease in inventories	(6.50)	-
(Increase)/decrease Trade and other receivables	140.31	(1,253.04)
Increase/(decrease) Trade Payables	(1,199.13)	1,202.32
Increase/(decrease) Other Financial Current Liabilities	1.77	0.15
Increase/(decrease) Other Current Liabilities	(5.22)	7.94
(Increase)/decrease Others Current Assets	(9.70)	-
(Increase)/decrease Others Non Current financial Assets	0.08	(0.08)
CASH GENERATED FROM OPERATIONS	(931.05)	(42.70)
Direct Taxes Paid	(18.94)	(4.86)
I NET CASH FLOW FROM OPERATING ACTIVITIES	(949.99)	7.96
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(0.00)	(0.66)
Investment in associates	(333.37)	
Loans & Advances Given	1,425.29	(3,777.74)
II NET CASH USED IN INVESTING ACTIVITIES	1,091.91	(3,778.40)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of shares	-	3,826.00
Proceeds/(Repaid) from Long term Borrowings	-	(57.17)
TDS on Interest	-	-
Finance cost paid	-	(1.58)
III NET CASH USED IN FINANCING ACTIVITIES	-	3,767.25
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	141.93	(3.19)
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	0.38	3.58
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	142.31	0.38

As per our report of even date

Note 1.The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)


RAVINDRAN GOVINDAN**CHAIRMAN & MANAGING DIRECTOR**

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900MH1993PLC288371 Results for the period ended September 30, 2024					
		(Amount in lakhs)			
		Quarter Ended		Half Year Ended	Year Ended
Particulars		30-09-2024	30-06-2024	30-09-2024	31-03-2024
		Unaudited	Unaudited	Unaudited	Audited
I)	Revenue From Operations	3,965.53	1,012.07	4,977.60	2,098.13
II)	Other Income	22.35	74.17	96.52	50.12
III)	Total Income (I+II)	3,987.87	1,086.25		2,148.25
IV)	Expenses :			-	
	Cost of Material Consumed	-	-	-	1,573.80
	Purchase of Traded Goods	4,086.33	1,751.84	5,838.16	7.87
	Changes in inventories of finished goods, by-products and work in progress	(473.77)	(890.39)	(1,364.17)	63.74
	Employee Benefit expenses	50.60	39.31	89.91	38.10
	Depreciation and Amortization Expenses	28.81	27.72	56.54	18.21
	Finance Cost	4.86	12.50	17.36	6.76
	Other Expenses	252.98	128.94	381.92	228.66
	Total Expenses (IV)	3,949.81	1,069.92	5,019.73	1,937.13
V)	Profit (Loss) Before exceptional and tax (III-IV)	38.07	16.32	54.39	211.12
VII)	Share of Loss from Associate	-	-	-	-
	- The Therapy Platform Pte Ltd	(6.22)	(3.61)	(9.83)	-
	- Bluesim tech pte ltd FS	(10.83)	(5.11)	(15.93)	-
	Profit/(loss) before exceptional items and tax (VII + VIII)	21.02	7.61	28.62	211.12
VI)	Exceptional Items	-	-	-	-
	Profit before tax (V-VI)	21.02	7.61	28.62	211.12
VIII)	Tax Expenses			-	
	i) Current Tax	5.00	(17.00)	(12.00)	(3.00)
	ii) Deferred Tax	3.31	(2.32)	1.00	(24.33)
		-	-	-	-
IX)	Profit (Loss) from Continuing Operations (VII-VIII)	29.33	(11.71)	17.62	183.79
XIII)	Profit (Loss) for the period (XI+XII)	29.33	(11.71)	17.62	183.79
XIV)	Other Comprehensive income;				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV)	Total Comprehensive Income for the period (Comprising profit/(loss) and other Comprehensive Income for the period (XIII-XIV)	29.33	(11.71)	17.62	183.79
XVI)	Net Profit attributable to				
	a) Owners of the Company			20.48	
	b) Non-Controlling Interest			(2.86)	
XVII)	Earnings per Equity Shares				
	1) Basic	0.05	(0.02)	0.03	1.65
	2) Diluted	0.05	(0.02)	0.03	1.08
	Summary of significant accounting policies				
	Notes to accounts				

As per our report of even date

1.The acquisition of 'M/s.Time Medical International Ventures (India) Private Limited' has been done during the Quarter four of the Previous financial year ended on 31st March 2024. Since consolidation has been done in the previous year quarter ended, There is No comparatives of previous year's figures as on quarter and period ended 30th Sept 2023.

2. M/s.Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited).during the period under review has made overseas investments in the following companies:-

i) Flynncare Health Innovations P Ltd dated 27th July 24 ,

ii) FMV Healthcare PTE Limited dated 26th Aug 24,

iii) FMV International Ventures PTE Limited dated 26th Aug 24 all the stated company will be considered as another material subsidiary following 'M/s.Time Medical International Ventures (India) Private Limited'

3. M/s.Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited).during the period under review has made overseas investments in Fischer Hospitality Sdn. Bdn. Dated -19th Sept 24 acquiring 60% of the Share Capital of the Company

For FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited)




RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900MH1993PLC288371

BALANCE SHEET AS AT September 30, 2024

Particulars	Notes No.	As At 30th September 2024	As At 31st March 2024
Assets			
(1) Non-Current Assets			
Property, Plant & Equipment		1,108.53	935.14
Goodwill		378.70	221.52
Deferred Tax Asset (Net)	2	1.66	-
Right of use Asset		288.88	314.30
		-	-
		-	-
Financial Assets			
(i) Investments		1,170.43	120.63
(ii) Other non - current assets		22.46	-
Total Non-Current Assets		2,970.66	1,591.60
(2) Current assets			
(a) Inventories		1,811.72	447.55
(b) Financial assets		-	-
(i) Trade receivables	3	7,575.42	2,286.96
(ii) Cash and cash equivalents	4	190.28	94.83
(iii) Bank balances other than cash and cash equivalents		356.70	3,699.77
(iv) Other Current Financial Asset		-	-
-Loans		6.14	-
-Other Current Financial Asset		818.71	305.31
(c) Current Tax Asset(Net)		12.45	-
(b) Other Current Assets	6	330.23	206.14
Total Current Assets		11,101.64	7,040.56
Total Assets		14,072.30	8,632.17
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital	7	5,350.00	5,350.00
(b) Other Equity	8	2,708.12	2,675.30
(c) Non Controlling Interest		122.74	-
(d) Money received against share warrants		87.15	87.15
Total Equity		8,268.01	8,112.45
Liabilities			
(1) Non-Current Liabilities			
(a) Deferred Tax Liability		11.40	12.40
(b) Financial Liabilities		-	-
(i) Borrowings		-	-
Lease Liabilities		-	125.10
Total Non-Current Liabilities		11.40	137.50
(2) Current Liabilities			
(a) Financial Liabilities		-	-
(i) Short Borrowings		-	-
Lease Liabilities		147.24	42.60
(ii) Trade payables	9	0	-
total outstanding dues of micro enterprises and small enterprises		5,418.13	79.88
total outstanding dues of creditors other than micro enterprises and small enterprises	10	3.02	135.67
(iii) Other Financial liabilities	11	102.65	102.80
Provision		0.90	0.90
(b) Other Current Liabilities	13	120.94	20.37
Total Current Liabilities		5,792.89	382.22
Total Equity and Liabilities		14,072.30	8,632.17
The accompanying notes are an integral part of the financial statements.			
As per our report of even date			

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900MH1993PLC288371

Cash Flow Statement as at September 30, 2024

(Amount in lakhs)

PARTICULARS	For the period ended 30-09-2024	For the year ended 31-03-2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit /(Loss) before tax and Extra Ordinary items	28.62	211.12
<u>Adjustment for:-</u>		
Finance Cost	12.64	2.68
Depreciation	31.13	9.05
Depreciation on ROU		9.16
Interest On lease liability	4.73	4.08
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	77.12	236.09
<u>Adjustment for:-</u>		
(Increase)/decrease inventories	(1,364.17)	1,752.11
(Increase)/decrease Trade and other receivables	(5,288.46)	(3,470.94)
Increase/(decrease) Trade Payables	5,205.60	993.89
Increase/(decrease) Other Financial Current Liabilities	(25.33)	100.39
Increase/(decrease) Other Current Liabilities	100.57	(8.69)
(Increase)/decrease Others current Financial Assets	(513.40)	(294.90)
(Increase)/decrease Others Non Current financial Assets	(22.46)	-
(Increase)/decrease Foreign currency translation report	7.54	
(Increase)/decrease Others Current Assets	(124.09)	(38.29)
CASH GENERATED FROM OPERATIONS	(2,024.19)	(966.43)
Direct Taxes Paid	(27.45)	(4.86)
I NET CASH FLOW FROM OPERATING ACTIVITIES	(1,974.52)	(735.20)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(204.52)	(48.49)
Purchase of Investments	(1,049.80)	(3,090.00)
Sale of Fixed Deposits	3,343.07	
Loans & Advances Given	(6.14)	(0.08)
II NET CASH USED IN INVESTING ACTIVITIES	2,082.61	-
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of shares	-	3,826.00
Lease Liability		(60.44)
Lease rent Paid		
Proceeds/(Repaid) from Long term Borrowings	-	(57.17)
Finance cost paid	(12.64)	(2.68)
III NET CASH USED IN FINANCING ACTIVITIES	(12.64)	3,705.72
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	95.45	(168.07)
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	94.83	3.58
Add:- CASH & CASH EQUIVALENTS POST ACQUISITION		259.32
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	190.28	94.83

##

As per our report of even date

Note 1.The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)


RAVINDRAN GOVINDAN**CHAIRMAN & MANAGING DIRECTOR**


Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended 30th September 2024 and for the year to date results for the period 1 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

1. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bilimoria Mehta & Co,
Chartered Accountants
FRN.: 101490W**





Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: 13-11-2024

UDIN: 24165824BKBZSO1276

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)


1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 September 2024 and consolidated year to date results for the period 1 April 2024, to 30 September 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs 12,090.50 Lakhs as at 30 September 2024, and year-to-date total revenues of Rs 4,977.59 lakhs and year-to-date total comprehensive loss of Rs 117.58 lakhs, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W





Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: 13-11-2024
UDIN: 24165824BKBZSP1889

ANNEXURE-1

List of Entities included in the statement:

<u>Sr no</u>	<u>Particulars</u>	<u>Stakes</u>	<u>Status</u>
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary
2	Time Medical Phillippines	75%	Subsidiary
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)

Details of Appointment Mr. Vivek Balasubramanian, Chief Financial Officer

S No.	Particulars	Details
1	Reason for change	The appointment is made pursuant to the recommendations of Nomination & Remuneration Committee.
2	Date of Appointment & terms of appointment	Date of appointment – Effective from –November 13, 2024 The Remuneration and other terms of the newly appointed Chief Financial Officer shall be governed by the Nomination and Remuneration Committee and the Board of Directors from time to time.
3	Brief profile (in case of appointment)	Vivek is a Chartered Accountant with a wealth of experience in the financial sector, having previously worked at PWC services LLP and KPMG India Services LLP as a lead in Mergers and Acquisitions. His strong track record includes successfully executing deals for leading corporations in the IT and automobile sectors. Additionally, Vivek brings a diverse background in statutory audits for multiple listed and unlisted companies in the sectors of shipping, ports, power, aviation, and automobile.
4	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not applicable
5	Information as required pursuant to BSE Circular with ref. No. LIST/COM P/14/2018-19 and the National Stock Exchange of India Ltd. with Ref. No. NSE/CML/2018/24, dated June 20,2018.	Not applicable

Details of Resignation of Mr. Dilip Suryakant Jha, Chief Financial Officer

S No.	Particulars	Details
1	Reason for change	Mr. Dilip Suryakant Jha has tendered his resignation from the position of Chief Financial Officer (Key Managerial Personnel) of the Company vide his letter dated November 08, 2024. He has decided to move on to pursue opportunities outside the Company.
2	Date of cessation	He will be relieved from the services of the Company with effect from close of business hour on November 12, 2024.
3	Brief profile (in case of appointment)	Not applicable
4	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not applicable
5	Information as required pursuant to BSE Circular with ref. No. LIST/COM P/14/2018-19 and the National Stock Exchange of India Ltd. with Ref. No. NSE/CML/2018/24, dated June 20,2018.	Not applicable
